286 related articles for article (PubMed ID: 32984844)
1. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.
Suresh S; Chen B; Zhu J; Golden RJ; Lu C; Evers BM; Novaresi N; Smith B; Zhan X; Schmid V; Jun S; Karacz CM; Peyton M; Zhong L; Wen Z; Sathe AA; Xing C; Behrens C; Wistuba II; Xiao G; Xie Y; Fu YX; Minna JD; Mendell JT; O'Donnell KA
Nat Cancer; 2020 May; 1(5):533-545. PubMed ID: 32984844
[TBL] [Abstract][Full Text] [Related]
2. eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
Li Q; Xiao M; Shi Y; Hu J; Bi T; Wang C; Yan L; Li X
BMC Cancer; 2021 Sep; 21(1):1022. PubMed ID: 34525951
[TBL] [Abstract][Full Text] [Related]
3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
4. eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA.
Wu Y; Xie J; Jin X; Lenchine RV; Wang X; Fang DM; Nassar ZD; Butler LM; Li J; Proud CG
Biochem J; 2020 Nov; 477(22):4367-4381. PubMed ID: 33094805
[TBL] [Abstract][Full Text] [Related]
5. DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion.
Chen B; Hu J; Hu X; Chen H; Bao R; Zhou Y; Ye Y; Zhan M; Cai W; Li H; Li HB
Nat Commun; 2022 Apr; 13(1):2059. PubMed ID: 35440133
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.
Cheng B; Ding K; Chen P; Ji J; Luo T; Guo X; Qiu W; Ma C; Meng X; Wang J; Yu J; Liu Y
Cancer Commun (Lond); 2022 Jan; 42(1):17-36. PubMed ID: 34981670
[TBL] [Abstract][Full Text] [Related]
7. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Depletion of eukaryotic initiation factor 5B (eIF5B) reprograms the cellular transcriptome and leads to activation of endoplasmic reticulum (ER) stress and c-Jun N-terminal kinase (JNK).
Bressler KR; Ross JA; Ilnytskyy S; Vanden Dungen K; Taylor K; Patel K; Zovoilis A; Kovalchuk I; Thakor N
Cell Stress Chaperones; 2021 Jan; 26(1):253-264. PubMed ID: 33123915
[TBL] [Abstract][Full Text] [Related]
10. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract][Full Text] [Related]
11. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract][Full Text] [Related]
12. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
13. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.
Shi S; Gu S; Han T; Zhang W; Huang L; Li Z; Pan D; Fu J; Ge J; Brown M; Zhang P; Jiang P; Wucherpfennig KW; Liu XS
Clin Cancer Res; 2020 Nov; 26(22):5990-6002. PubMed ID: 32723834
[TBL] [Abstract][Full Text] [Related]
14. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM
J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362
[TBL] [Abstract][Full Text] [Related]
15. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
16. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
17. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
18. WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function.
Yoon HJ; Kim GC; Oh S; Kim H; Kim YK; Lee Y; Kim MS; Kwon G; Ok YS; Kwon HK; Kim HS
Exp Mol Med; 2022 Nov; 54(11):1913-1926. PubMed ID: 36357569
[TBL] [Abstract][Full Text] [Related]
19. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
